CE IVD

Precision in Hemostasis

Behnk Elektronik

BE PT LI Thromboplastin low ISI

Reagent for determination of Prothrombin time (PT) in human plasma

REF 771100: RE (5 x 5 mL), DIL (2 x 15 mL)
REF 771101: RE (8 x 12 mL), DIL (8 x 12 mL)

| INTENDED USE

This reagent is designated for professional use in laboratory (semi-automated or automated method). It is used for the chronometric determination of the Prothrombin time (INR) in human plasma to explore the extrinsic coagulation pathway and monitor VKA treatments.

PRINCIPLE [4]

Quick et al. method:
The clotting time is measured at 37 °C in the presence of tissular thromboplastin and calcium. It reflects the activity of Factor II (prothrombin), V (proaccelerin), VII (proconvertin), X (Stuart Factor) and fibrinogen. The measured time is converted into PT (%) or INR.

GENERALITIES [1] [6] [7]

The Prothrombin time (PT) is a useful basic coagulation screening test to investigate the extrinsic coagulation pathway. PT (in sec.) converted into PT (%) allows the evaluation of the prothrombinic activity, referring to a normal plasma (100 %).
A deficient prothrombinic activity is found in the following clinical states:
• Hemorrhagic disease of the newborn
• Liver failure (cirrhosis, hepatitis...)
• Vitamin K deficiency or treatment with vitamin K antagonists
• Congenital deficits in one of the factors associated with the prothrombinic complex, real prothrombin (factor II), proaccelerin (factor V), proconvertin (factor VII) and Stuart's factor (factor X)
• Circulating anticoagulants
• Fibrinolysis
• DIC (disseminated intravascular coagulation)
Monitoring of treatment with vitamin K antagonists:
The PT (in sec.) may be converted into INR (International Normalized Ratio). In that case, the origin of the thromboplastin has no incidence on the determination of the expected values. An international standardization about INR reference intervals has been established for treatment and prophylaxis of venous and arterial thromboembolisms.
Avoid results in INR in the case of pre-operative check-up or investigations for liver diseases.

REAGENTS

RE **PT LI** Freeze-dried Thromboplastin
Rabbit cerebral tissue

According to 1272/2008 regulation, this reagent is not classified as dangerous.

DIL **PT Diluent** Reconstitution Buffer **Attention**

HEPES buffer, calcium.
Skin Sens.1: H317 - May cause an allergic skin reaction.
P261: avoid breathing sprays, P280: Wear protective gloves/protective clothing/eye protection/face protection, P302+352: IF ON SKIN: Wash with soap and water.
P333+313: If skin irritation or a rash occurs: Get medical advice/attention,
P501: Dispose of contents/container in accordance with dangerous goods regulations.
Classification due to: Nickel Sulfate < 1%. For more details refer to current Material Safety Data Sheet (MSDS)
Once reconstituted: Working Reagent (vial RE) is classified as Buffer (vial DIL)

SAFETY CAUTIONS

- Refer to current Material Safety Data Sheet available on request or on www.behnk.de
- Verify the integrity of the contents before use.
- Waste disposal: Respect legislation in force in the country.
- All specimens or reagents of biological origin should be handled as potentially infectious. Respect legislation in force in the country.

| Any serious incident that has occurred in connection with the device is notified to the manufacturer and the competent authority of the Member State in which the user and/or patient is based.

PREPARATION OF REAGENTS

RE: Reconstitute the lyophilizate with the amount of DIL indicated on the label of RE. Cap vials and mix gently the RE vial until complete dissolution.
DIL: Ready for use.

STABILITY AND STORAGE

Unopened vials, stored away from light at 2-8 °C are stable until the expiry date stated on the label.
Stability after reconstitution:

- 2-8 °C 7 days
- On board Stability (OBS)* 3 days
- Laboratory mode** 7 days
- 37 °C 8 hours

* 18-22 °C, stirred
** Laboratory mode = 8 hours on board; 16 hours well capped in the original vial at 2-8 °C.

Do not use any reagent after expiry date.

SAMPLES COLLECTION AND HANDLING [2] [8]

Plasma from careful venipuncture with anticoagulant ratio of 1/10 (sodium citrate solution 0.109 M). Mix immediately the blood with anticoagulant.
Avoid drawing with a syringe that could result in the formation of micro-clots.
Centrifuge 10 minutes at 2500 g.
The specimen is stable 4 hours after collection, at room temperature (15-25 °C).
Collection on Citrate Hepes tube increases the sample stability to 8 hours.

LIMITS [2] [3]

Samples contaminated by thromboplastin or hemolysis may shorten the result of PT (in sec.).
For a more comprehensive review of factors affecting this assay, refer to the publication of Young D.S.

MATERIAL REQUIRED BUT NOT PROVIDED

Basic medical analysis laboratory equipment
Automated or semi-automated coagulation analyzer
REF 050813: Magnetic stirrers 8 x 1.5 mm, for Behnk Thrombolyzer series.

REFERENCE RANGE [2] [6] [9]

PT (sec): Normal values between 11 and 16 sec.
PT (%): Normal values 70 % to 100 %. Values over 100 % are considered as normal.

PT (INR): Oral anticoagulant therapy (OAT):

Indications	Therapeutic range in INR		PT (%) Rabbit thromboplastin
	Target	Acceptable range	
Pre-operative and during surgery:			
Hip surgery	2.5	2.0 – 3.0	35 %
Other surgery	2.0	1.5 – 2.5	40 %
Venous thrombosis prophylaxis	2.5	2.0 – 3.0	35 %
Evolutive phlebitis, pulmonary embolism, recurrent phlebitis	3.0	2.0 – 4.0	27 %
Arterial prophylaxis, mechanical prosthetic valves	3.5	3.0 – 4.5	25 %

QUALITY CONTROL

REF 773100: BE Trol 1; REF 773101: BE Trol 2
Controls are required for checking the accuracy and reproducibility of the results.
The control intervals should be adapted to each laboratory's individual requirements.
Values obtained should fall within the defined limits.
Follow the applicable government regulations and local guidelines for quality control.

PROCEDURE

Manual method on semi-automated systems
Pre-incubate reagent 15 min to reach a temperature of 37 °C and mix gently before use:

- Plasma: 100 µL

Incubate for 120 sec at 37 °C

- Thromboplastin (37 °C): 200 µL

The automatic countdown timer will start immediately after Thromboplastin addition and stop when the clot is formed.
Automated method on Behnk Thrombolyzer series
Refer to the full detailed application specific to the automated system.
Note:

- Performances and stability data have been validated on Thrombolyzer Compact X (available on request).
- With manual procedure and on other automated coagulation analyzer, performances and stability data must be validated by user.
- Other validated applications or proposal applications are available on request.

CALIBRATION

PT INR and % with Calibrator Set
Use calibrator set REF 775200: BE Cal Set
Automated method on Behnk Thrombolyzer series:

- Perform a Calibrator Set calibration with BE Cal Set.

Manual method on semi-automated systems (PT %):

- Prepare a calibration curve with Cal1, Cal2 and Cal3.
- Measure in triplicate the clotting time of each level.

PT INR with MNPT and ISI (all methods)

- MNPT (Mean Normal Prothrombin Time)

To determine the MNPT prepare a pool of freshly collected normal plasmas. Measure in triplicate the clotting time and calculate the mean.

- ISI (ISI (International Sensitivity Index): See enclosed batch specific table.

It has been determined by testing human plasmas with this Thromboplastin and with an Internal Reference Thromboplastin traceable to RBT16 (WHO International Standard Thromboplastin, Rabbit plain).

Manufactured by
BIOLABO S.A.S.
Les Hautes Rives
02160 Maizy, France

Distributed by
Kommanditgesellschaft Behnk Elektronik GmbH & Co.
Hans-Böckler-Ring 27
22851 Norderstedt, Germany

T. +49 (0)40-529 861 0
F. +49 (0)40-529 861 99
info@behnk.de

Made in France

Latest revision: www.behnk.de

Obtained PT (sec values) with the 2 thromboplastins were plotted on log to log graph and the slope was calculated. ISI was then calculated multiplying the slope by ISI of the Internal Reference Thromboplastin.

CALCULATION [6]

PT INR and PT % with Calibrator Set
Automated method on Behnk Thrombolyzer series:
PT INR and PT % will be calculated automatically according to two calibration curves.

Semi-automated systems: Enter the mean of the clotting time found for each BE Cal Set plasma and the corresponding PT % in the system. PT % concentration will be calculated automatically according to calibration curve.

PT INR with MNPT and ISI of the reagent (all methods)
The MNPT and ISI are to be used to calculate result in INR.
Calculate INR as follows: $INR = (\text{Patient time} / MNPT)^{ISI}$

Manual Procedure:
Refer to enclosed batch specific table, selecting the suitable column according the MNPT.

- Identify the patient's PT (sec.) in this column.
- On the same line, refer to the corresponding PT (%) or INR.

For semi-automated systems and Behnk Thrombolyzer series the INR will be calculated automatically after input in the system.

PERFORMANCES

The within run and between run studies were performed on Thrombolyzer Compact X.

Precision:

Within run N = 20	Level 1	Level 2	Level 3
Mean (%)	96.6	30.3	16.4
S.D. (%)	0.98	0.54	0.39
C.V. %	1.0	1.8	2.4

Between run N = 20	Level 1	Level 2	Level 3
Mean (%)	96	30.4	16.7
S.D. (%)	1.81	0.99	0.47
C.V. %	1.9	3.3	2.8

Comparison with commercially available reagent, same method: 167 plasmas located between 14% and 110%:
y = 1.1376x – 1.4301
r= 0.9958

Interferences (sec, INR):

Turbidity	No interference up to 731 mg/dL of Triglycerides
Low Molecular weight heparin	Positive interference from 0.114 IU anti Xa
Unfractionated heparin	Positive interference from 0.038 IU anti Xa
Bilirubin	Positive interference from 238 µmol/L
Hemoglobin	No interference up to 258 µmol/L

Other substances may interfere with the results (see § Limits)

Calibration Stability: Make a new calibration when changing reagent batch, if quality control results are found out of the established range and after maintenance operations.

REFERENCES

(1) *Caen J., Larrieu MJ, Samama M : « L'hémostase. Méthodes d'exploration et diagnostic pratique » Paris : L'Expension Scientfique, p.344-347, (1975).*

(2) *Clinical Guide to Laboratory Test, 3rd Ed., N.W. TIETZ (1995) p.526-529*

(3) *YOUNG D.S., Effect of Drugs on Clinical laboratory Tests, 4th Ed. (1995) p.3-513 à 3-517*

(4) *Quick A. J.- J. Am. Assoc., (1938),* ***110****,p. 1658-1662*

(5) *Duckert F., Marbet G.A. - Méd., et Hyg., (1977),* ***35****, p. 911*

(6) *Goguel A.F. - Feuillets de Biologie, (1985),* ***36****, (146) p. 25-28.*

(7) *Houbouyan-Reveillard et al. Spectra biologie (2003) vol.22, n°132 p.33-37*

(8) *Neofotistos D, Oropeza M., Ts'ao C-H : « Stability of plasma for add-on PT and PTT tests » Am. J. Clin. Pathol. 109, 6, 758-763, (1998).*

(9) *Sampol J., Arnoux D., Boutière B. : « Manuel d'hémostase » Paris, Ed. Elsevier, 147-163 (1995)*

| = Significant modifications

IFU_771100-771101-EN_V02_20230601

Manufacturer	Expiry date	In Vitro Diagnostic	Temperature limitation	Catalogue number	See insert	Batch number	Store away from light	Sufficient for	Dilute with	Demineralized water	Biological hazard
		IVD		REF		LOT		Σ	→	H2O	

Manufactured by
BIOLABO S.A.S.
Les Hautes Rives
02160 Maizy, France

Made in France

Distributed by
Kommanditgesellschaft Behnk Elektronik GmbH & Co.
Hans-Böckler-Ring 27
22851 Norderstedt, Germany

T. +49 (0)40-529 861 0
F. +49 (0)40-529 861 99
info@behnk.de

Latest revision: www.behnk.de